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Abstract
Objective:  To  describe  the  genotypic  variability  of  group  A  rotavirus  (RVA)  found  in  immuno-
suppressed and  non-immunosuppressed  pediatric  patients  treated  at  the  Hospital  de  Clínicas
da  Universidade  Federal  do  Paraná  (HC-UFPR),  Curitiba,  Paraná.
Methods:  A  cross-sectional  study  was  conducted  with  1,140  stool  samples  collected  from  April,
2001 to  December,  2008  in  outpatients  and  hospitalized  patients  with  acute  gastroenteri-
tis referred  to  the  hospital.  RVA  diagnosis  was  performed  through  the  latex  agglutination
method and  enzyme  immunoassay.  Reverse  transcription  followed  by  multiplex  hemi-nested
polymerase  chain  reaction  (PCR)  and  nucleotide  sequencing  were  used  for  genotype  charac-
terization.  Genotype  combinations,  clinical,  epidemiological,  laboratory  data,  and  presence  of
hospital-acquired  infections  were  reported.
Results:  A  total  of  80  rotavirus-positive  stool  samples  were  analyzed.  The  most  frequent
associations between  genotypes  G  and  P  were:  G4  P[8]  (38.9%),  G1  P[8]  (30.5%),  G9  P[8]
(13.9%),  G2  P[4]  (6.9%),  and  G3  P[8]  (1.4%).  G2  P[4]  was  the  most  prevalent  genotype  after
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the  vaccine  implementation  in  the  years  2006  and  2008.  A  total  of  62,5%  of  infected  children
were  aged  less  than  12  months.  Of  these,  55.6%  had  severe  dehydration  and  26.7%  needed
intensive  care.  A  frequency  of  12.5%  of  nosocomial  infections  was  found.  No  correlation  was
observed  between  genotype  and  severity  of  infection  in  the  study  patients.
Conclusion: RVA  infections  can  be  associated  with  severe  clinical  manifestations,  and  the
surveillance of  genotypic  variability  of  this  virus  is  crucial  to  monitor  the  emergence  of  new
strains  and  the  impact  of  the  immunization  in  these  patients.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Caracterizac¸ão  molecular  dos  genótipos  do  rotavírus  em  pacientes  pediátricos
imunossuprimidos  e  não  imunossuprimidos
Resumo
Objetivo:  Descrever  a  variabilidade  genotípica  do  rotavírus  grupo  A  (RVA)  encontrado  em
pacientes pediátricos  imunocompetentes  e  imunocomprometidos  tratados  no  Hospital  de  Clíni-
cas/Universidade  Federal  do  Paraná  (HC/UFPR),  Curitiba,  Paraná.
Métodos: Foi  realizado  um  estudo  transversal  com  1.140  amostras  de  fezes  coletadas,  de
abril de  2001  a  dezembro  de  2008,  em  pacientes  ambulatoriais  e  pacientes  hospitalizados
com gastroenterite  aguda  encaminhados  ao  hospital.  As  técnicas  usadas  foram  o  método
da  aglutinac¸ão  do  látex  e  imunoensaio  enzimático  para  diagnóstico  de  RVA.  Foi  realizada
transcric¸ão  reversa,  seguida  por  PCR  multiplex  semi-nested  e  sequência  de  nucleotídeos  para
caracterizac¸ão  do  genótipo.  Foram  relatadas  as  combinac¸ões  genotípicas,  dados  clínicos,  epi-
demiológicos,laboratoriais  e  a  presenc¸a de  infecc¸ões  hospitalares.
Resultados:  Foi  analisado  um  total  de  80  amostras  de  fezes  positivas  para  rotavírus.  As
associac¸ões mais  frequentes  entre  os  genótipos  G  e  P  foram:  G4  P[8]  (38,9%),  G1  P[8]  (30,5%),
G9  P[8]  (13,9%),  G2  P[4]  (6.9%)  e  G3  P[8]  (1.4%).  O  genótipo  prevalente  foi  G2  P[4]  depois
da  implementac¸ão  da  vacina  nos  anos  de  2006  e  2008.  Veriﬁcou-se  que  um  total  de  62,5%
das  crianc¸as  infectadas  tinham  idade  abaixo  de  12  meses.  Destas,  55,6%  tinham  desidratac¸ão
grave, e  26,7%  precisaram  de  cuidados  intensivos.  Encontrou-se  uma  frequência  de  12,5%  de
infecc¸ões  hospitalares.  Não  se  observou  correlac¸ão  entre  o  genótipo  e  a  gravidade  da  infecc¸ão
nos pacientes  estudados.
Conclusão: As  infecc¸ões  por  RVA  podem  associar-se  a  manifestac¸ões  clínicas  graves  e  é  crucial  a
vigilância  da  variabilidade  genotípica  desse  vírus  para  monitorizar  a  emergência  de  novas  cepas
e  o  impacto  da  imunizac¸ão  nesses  pacientes.
©  2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Group  A  rotaviruses  (RVA)  are  the  major  etiologic  agents
of acute  watery  diarrhea  in  children  aged  less  than  5
years worldwide.  On  a  global  scale,  they  are  responsible
for approximately  611,000  deaths  per  year,  mostly  in  low-
income countries.1
RVA  infections  remain  an  important  cause  of  pediatric
hospitalization, particularly  in  developing  countries,  where
demographic and  socio-economic  factors  are  associated
with increased  mortality  rates.  Vaccination  has  a  signiﬁcant
impact on  the  frequency  of  disease;  nevertheless,  severe
infections persist,  and  the  possible  emergence  of  new  geno-
types must  be  considered.  The  diversity  of  rotavirus  strains
underscores the  need  for  intensive  strain  surveillance;  thus,
the implementation  of  laboratory  surveillance  is  critical  to
prevent outbreaks.2
Rotaviruses  are  classiﬁed  into  seven  major  groups  (A
through G),  but  most  of  infections  are  associated  to  rotavirus
A, although  groups  B  and  C  have  been  found  in  human  ill-
ness. Among  RVA,  distinct  genotypes  (G  and  P  outer  capsid
antigen) have  been  described,  with  G1P[8],  G2P[4],  G3P[8],
a
t
v4P[8],  and  G9P[8]  the  most  commonly  identiﬁed  worldwide
nd in  Brazil.3
Several  reports  have  demonstrated  the  importance  of  this
athogen as  responsible  for  hospitalization  of  children  with
cute gastroenteritis  (AGE).  In  Brazil,  epidemiological  ﬁnd-
ngs suggest  detection  rates  ranging  from  12%  to  42%.4 The
ospital de  Clínicas  da  Universidade  Federal  do  Paraná  (HC-
FPR) is  a  tertiary  center  that  receives  patients  referred
rom Curitiba  and  the  metropolitan  region.  Analyzes  of  the
ause of  all  cases  of  gastroenteritis  admitted  to  the  HC-UFPR
ave shown  that  RVA  is  the  most  frequently  found  pathogen
20%) in  the  studied  population.5
In  2006,  two  rotavirus  vaccines  became  available,  a
onovalent rotavirus  vaccine  (Rotarix®,  GlaxoSmithKline
iologicals Inc)  and  a  pentavalent  rotavirus  vaccine  (RV5;
otaTeq®, Merck  &  Co.,  Inc.).  Both  vaccines  are  recom-
ended by  the  World  Health  Organization  (WHO)  and  have
een used  in  several  countries,  and  they  have  demonstrated
 signiﬁcant  reduction  of  hospitalization  and  mortality  due
o rotavirus  gastroenteritis.6,7
Brazil  was  one  of  the  ﬁrst  countries  to  introduce  universal
accination against  RVA,  Rotarix®,  which  has  been  provided
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ree  through  the  public  health  system  since  March  of  2006.
he vaccine  coverage  in  all  the  country  in  2006  and  2007  was
0% and  75%,  respectively.8 However,  the  South  and  South-
ast Regions  had  the  highest  vaccine  coverage,  and  it  the
argest reduction  in  the  rate  of  hospitalization  of  children
ue to  AGE  was  observed  there.9
Previous  analysis  conducted  in  2009  at  this  hospital  to
ssess the  impact  of  vaccination  against  RVA  showed  a reduc-
ion of  54.2%  and  39.4%  in  medical  consultations  for  children
ess than  12  months  old  and  between  12  and  60  months,
espectively. Furthermore,  there  was  a  reduction  of  43.9%
nd 33.3%  in  the  number  of  hospitalizations  for  gastroen-
eritis in  children  under  12  months  and  aged  12--60  months,
espectively, considering  the  coverage  of  around  80%  in  the
bovementioned period  (unpublished  data).  Epidemiologi-
al surveillance  for  RVA  diarrheal  illness  was  established  in
he country  to  monitor  the  genotypic  diversity  of  circulating
VA, as  well  as  the  rise  of  emerging  and  re-emerging  RVA
trains .10
Several  studies  involving  the  genetic  variability  of  RVA
ave been  published  in  Brazil;  nonetheless,  the  major-
ty of  these  were  conducted  in  the  Central  and  Southeast
egions, and  the  information  about  other  regions  is  scarce.
his study  aimed  to  describe  RVA  genotypic  variability
ver an  eight-year  period,  and  to  assess  clinical  and  epi-
emiological features  of  infected  patients,  as  well  as
he impact  of  the  immunization  program  on  viral  genetic
iversiﬁcation.
ethods
amples  and  study  design
his  was  a  cross-sectional  study  that  involved  the  examina-
ion of  1,140  stool  samples  of  outpatients  and  inpatients
ith acute  gastroenteritis  referred  to  HC--UFPR.  The
atients were  admitted  to  pediatric  wards  or  to  the
ematopoietic stem  cells  transplantation  (HSCT)  unit.  The
tool samples  were  collected  from  April  of  2001  to  Decem-
er of  2008,  and  were  sent  to  the  virology  laboratory  for  RVA
etection and  posterior  genotyping  studies.  Medical  records
f infected  patients  were  reviewed,  and  the  clinical  data
ere collected  using  speciﬁc  forms.
This  study  was  approved  by  the  Ethics  of  Research  on
uman Beings  Committee  of  the  HC-UFPR,  under  registra-
ion No.  4441.023/2002-04.
riteria  for  the  classiﬁcation  of  severity  of
ehydration
ehydration  was  classiﬁed  as  mild,  moderate,  or  severe,
nd evaluated  on  a  clinical  dehydration  scale  for  children
s previously  reported.11
etection  of  viral  antigenecal  samples  were  initially  tested  for  group  A  rotavirus
ntigen by  screening  tests  -  LA,  (Virotect  Rota  kit--Omega
iagnostics or  Rotascreen  kit--Microgen  Bioproducts)  and
IA (EIARA  kit--Biomanguinhos  or  Rotascreen  II  kit--Microgen
R
D
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ioproducts),  according  to  the  manufacturer’s  instructions.
he performance  of  these  methods  was  analyzed  and  their
esults were  compared  to  those  previously  reported.12 Pos-
tive samples  were  sequentially  analyzed  by  molecular
ethods.
iral  genomic  RNA  extraction  and  multiplex
emi-nested RT-  PCR
enomic  RNA  was  extracted  using  aliquots  of  200  L  of  fecal
uspension (10%  wt/vol)  and  silica  ﬁlter,  in  accordance  with
he process  previously  described.13 The  RNA  obtained  was
nalyzed by  a  multiplex  hemi-nested  real  time  polymerase
hain reaction  (RT-PCR)  to  deﬁne  the  viral  genotype,  using
reviously described  methods.13 Brieﬂy,  the  RNA  was  reverse
ranscribed and  ampliﬁed  by  using  speciﬁc  primers  corre-
ponding to  a  conserved  nucleotide  sequence  of  the  VP4  and
P7 genes,  fragments  of  876  bp  and  904  bp,  respectively.13
he  ampliﬁed  fragment  was  used  as  a  template  to  a  second
CR, using  a  combined  typing  scheme  of  the  pool  of  primers
o identify  VP7:  pool  A  (G1,  G2,  G3,  G4,  and  G5),  pool  B  (G8,
9, and  G10),  and  pool  C  (G6  and  G11);  and  to  identify  VP4:
ool A  [P4],  [P6],  [P8],  [P9],  and  pNCDV  [P1]  genotypes.  The
esults obtained  were  conﬁrmed  with  individual  primers  for
he identiﬁed  genotype.
equencing,  assembling  and  nucleotide  sequence
omparison
amples  that  were  positive  in  the  ﬁrst-step  PCR,  and  which
ould not  be  genotyped  by  multiplex  nested  PCR  were  ana-
yzed by  nucleotide  sequencing.  The  PCR  products  were
uriﬁed using  Invisorb®  Spin  PCRapid  kit  (Invitek  Inc--USA),
fter both  DNA  strands  were  directly  sequenced  as  described
n the  Thermo  Sequenase  kit  (USB  Inc  --  Ohio,  USA)  man-
al. BigDye®  Terminator  method  was  used  on  an  ABI  3100
Applied Biosystems  Inc  --  USA).  Speciﬁc  primers  from  the
rst and  second  PCR  were  used  to  detect  the  RVA.
The  BioEdit  Sequence  Alignment  Editor  was  used  to
ssemble the  fragments  into  the  most  likely  sequence.14
 set  of  VP4  and  VP7  segment  sequence  was  retrieved
rom Genbank,15 comprising  representative  RVA  geno-
ypes. Nucleotide  differences  were  quantiﬁed  using  the
egaAlignTM software  (DNASTAR®,  Inc  -  USA).
All  molecular  analysis  and  sequencing  reactions  were  per-
ormed at  the  virology  laboratory  of  HC/UFPR.
tatistical  analyses
tatistical  analysis  was  performed  using  the  chi-squared
est or  Fisher’s  exact  test,  as  appropriate.  The  tests  were
erformed using  GraphPad  Prism  version  5.0  for  Windows
GraphPad Software  --  San  Diego,  California,  USA).  Only  two-
ailed tests  were  used.  A  p-value  of  <  0.05  was  considered
tatistically signiﬁcant.esults
uring  the  study  period,  179  (179/1,140  -  15.7%)  samples
ere positive  for  RVA;  of  these,  80  (80/179  --  44.7%)  had
Molecular  characterization  of  rotavirus  281
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Figure  1  Seasonality  of  rotavirus-positive  specimens  according  to  temperature  (◦C)  and  rainfall  (mm)  in  the  period  from  April,
A
G
D
A
6
w
o
f
5
t
p
p
s
i
w
m
C2001  to  December,  2008,  Curitiba,  Brazil.
enough  samples  for  further  analysis,  and  were  selected
for the  performance  of  multiplex  hemi-nested  RT-PCR  for
genotypes determination  and  nucleotide  sequence,  when
necessary. 72  samples  (72/80  -  90%)  were  RT-PCR  posi-
tive for  RVA;  of  these,  78%  (56/72)  were  from  hospitalized
patients.
Fig. 1  shows  the  distribution  of  RVA  during  the  eight-year
study and  its  relation  to  monthly  average  temperature  (◦C)
and rainfall  (mm).
G  and  P  combinations
Sixty-six  (66/72  --  91.6%)  samples  were  genotyped.  The
genotypes found  were  G4  P  [8]  (28/72  --  38.9%),  G1  P  [8]
(22/72 --  30.5%),  G9  P  [8]  (10/72  --  13.9%),  G2  P  [4]  (5/72
-- 6.9%),  and  G3  P[8]  (1/72  --  1.4%).  Six  samples  could  not
be sequenced,  probably  because  the  primers  used  did  not
correspond to  genotype  investigated;  also,  these  samples
presented a  weak  band  in  the  agarose  gel,  undermining  the
quality of  sequencing  reactions  performed.  Differences  in
G and  P  genotype  distribution  were  detected  in  distinct
years, reﬂecting  the  yearly  change  in  epidemiology  of  human
rotavirus, with  an  alternation  between  genotypes  every  one
or two  years  (ﬁg.  2).  No  mixed  RVA  infections  were  detected.
G1 P[8]
G4 P[8]
G9 P[8]
G8 P[8]
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Figure  2  P/G  genotype  combinations  among  rotavirus  identi-
ﬁed from  2001  to  2008,  Brazil.
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2 P  [4]  and  GNT  P  [8]  genotypes  were  found.
emographic  and  clinical  data
 total  of  69  (69/80  - 86.2%)  medical  records  were  reviewed.
5% of  the  patients  were  male.  The  median  age  of  patients
as nine  months  (IQR,  6  -  16.5  months),  and  most  cases
ccurred in  patients  aged  <  12  months.  Despite  the  broad
requency of  patients  with  underlying  diseases,  a  total  of
1% (37/72)  of  the  patients  were  admitted  primarily  due
o severity  of  diarrhea.  Regarding  the  vaccination  status  of
atients admitted  after  2006,  only  two  patients  reported
revious RVA  immunization:  one  received  the  complete
cheme and  the  other  only  the  ﬁrst  dose;  both  were  non-
mmunosuppressed patients.
For  clinical  and  laboratory  data  analysis,  the  patients
ere divided  into  two  groups  according  to  age:  children  ≤  12
onths (65%,  45/69)  and  children  >  12  months  (35%,  24/69).
omparison of  the  clinical  ward  showed  a  greater  frequency
f patients  <  12  months  in  the  intensive  care  unit  (ICU)
p =  0.008).  A  total  of  64%  of  children  presented  dehydration,
f which  78.3%  were  ≤  12  months  (p  =  0.01)  (Table  1).  Three
3.7%) children  evolved  to  death,  one  related  to  gastroen-
eritis. No  statistically  signiﬁcant  differences  were  observed
n the  comparison  between  genotype  and  presence  of  dehy-
ration (p  =  0.86).
VA  and  hospital-acquired  infections
osocomial  infections  were  considered  those  occurring
2 hours  after  admission.  From  a  total  of  72  RVA-positive
atients, 9  (12.5%)  had  diarrhea  after  this  period.  Of  these,
our patients  were  hospitalized  in  the  pediatric  emergency
nd ﬁve  in  pediatric  infectious  disease  settings.  The  median
ength of  hospitalization  was  seven  days  (IQR  four  to  12.5
ays) (Table  2).
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Table  1  Clinical  and  laboratory  data  of  patients  (n  =  69  patients)  with  acute  gastroenteritis  due  to  group  A  rotavirus,  Hospital
de  Clínicas/Universidade  Federal  do  Paraná,  2001  to  2008.
≤  12  months  n(%)  >  12  months  n(%)  Total  p-value
Clinical  data
Vomit
Yes 42  (72.4)  16  (27.6)  58  0.23
Fever
Yes  27  (64.3)  15  (35.7)  42  0.29
Number  of  evacuations/day
≤ ﬁve  times 16 (66.7) 8 (33.3)  24  0.54
>  ﬁve  times 23 (76.7) 7 (23.3) 30
Co-morbidities±
Yes  25  (36.8)  9  (13.2)  34  0.43
HIV  3  (12)  -  25
ALL/AML  -  2  (22.2)  9
Other  22  (88)  7  (77.8)  34
Severity  of  dehydration
Mild 10  (22.2)  2  (8.3)  12  0.013*
Moderate  1  (2.2)  1  (4.2)  2
Severe  25  (55.6)  7  (29.2)  32
Without  dehydration  5  (11.1)  8  (33.3)  13
Unknown  4  (8.9)  6  (25.0)  10
Length  of  hospitalization
Median 10  6  0.29
(IQR)  (days)  (3--17)  (1.5--7)
Antibiotic  therapy
Yes 30  (75.0)  10  (25.0)  40  0.23
Intensive  care  unit  12  (100)  0  12  0.008
Deaths 2  (66.7)  1  (33.3)  3  1.00
Data are shown as number (percentage), unless otherwise indicated.
ALL,  acute lymphocytic leukemia; AML, acute myeloid leukemia; HIV, human immunodeﬁciency virus; IQR, interquartile range; n, number
of samples.
* p-value calculated comparing presence or absence of dehydration.
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he  introduction  of  the  RVA  vaccine  in  the  national  immu-
ization schedule  contributed  to  a  signiﬁcant  reduction  in
he frequency  of  this  infection  in  the  pediatric  population.
owever, this  pathogen  can  be  associated  with  severe  dis-
ase, and  the  surveillance  of  its  genotypic  variability  is
rucial to  monitor  the  emergence  of  new  strains  circulating
n humans.
The variation  of  G  and  P  genotypes  observed  in  dif-
erent years  highlights  the  mechanisms  used  by  the  RVA
o escape  immune  selective  pressure  and  thus  maintain
he pathogen  in  nature.  Analysis  of  combinations  of  geno-
ypes G  and  P  type  have  demonstrated  that  genotype  G1
[8] was  predominant  in  2001  and  2003,  similar  to  pre-
ious ﬁndings.13 The  genotype  G3  P[8]  was  identiﬁed  in
nly one  sample  in  2003.  Regarding  genotype  G4  P[8],  its
ccurrence was  detected  in  2001,  as  the  second  most  fre-
uent genotype,  and  in  2002  it  prevailed;  similar  results
ere reported  in  Paraguay.16 The  genotype  G9  P[8]  was
dentiﬁed in  this  study  in  the  years  2002,  2004,  and  2005.
w
e
o
vccording  to  some  reports,17 this  genotype  is  now  circulat-
ng more  widely.  Genotype  G2  P[4]  has  re-emerged  since
006, and  it  has  become  predominant  in  the  samples  ana-
yzed in  this  study,  as  well  as  in  other  studies  in  Brazil  and  in
ther countries.18 In  year  2007,  no  RVA  was  detected  in  the
tudied samples;  however,  some  reports  in  Brazil  showed
he continuity  of  the  detection  of  G2  P[4]  genotype  until
008.19
These  results  demonstrate  the  ability  of  RVA  genetic
ariation, and  point  out  the  need  for  constant  surveillance
f the  circulating  genotypes.20 After  the  introduction  of
niversal vaccination  in  Brazil,  the  emergence  of  geno-
ypes G2  P[4]  and  G9  P[8]  was  observed.  The  impact  of
hese infections  must  be  monitored  in  order  to  assess
he effectiveness  of  the  currently  available  vaccines.  The
redominance of  genotype  G2  P(4)  in  other  countries  using
he Rotarix  vaccine  has  been  reported.  It  remains  unclear
hether this  is  due  to  selective  pressure  or  changing
pidemiology.21 However,  an  increase  of  the  frequency
f G2  P[4]  genotype  could  be  observed  in  periods  pre-
ious to  vaccine  implementation  and  also  in  countries
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ithout  RVA  immunization,18,22 and  thus  its  circulation  was
robably associated  to  the  natural  reemergence  of  this
enotype.3,23
Similar  to  previous  ﬁndings,  in  this  study  a  signiﬁcant
ecrease in  the  frequency  of  RVA  infections  in  the  pedi-
tric population  was  observed  since  the  implementation
f immunization,  and  the  positive  cases  observed  concern
atients with  incomplete  immunization  status  or  immuno-
uppressed patients,  who  may  not  develop  a complete
mmune response.  After  2006,  no  RVA-positive  samples  were
etected  in  outpatients.
RVA infections  are  most  common  in  the  wintertime  in
emperate regions,  and  year-round  in  tropical  areas.24 In  the
resent study,  an  increase  in  positive  cases  was  observed
n certain  years,  particularly  during  the  colder  months,  in
greement with  other  ﬁndings.13 However,  it  has  been  found
hat the  frequency  of  the  disease  varied  throughout  the  year,
uggesting that  factors  other  than  weather  can  inﬂuence
he seasonality  of  this  pathogen.25 Furthermore,  in  2008,
t was  observed  that  RVA  activity  was  spread  throughout  the
ntire year,  peaking  in  the  spring,  which  represented  a  delay
f almost  ﬁve  months  when  compared  to  pre-immunization
eriod. This  was  probably  a  result  of  a  less  susceptible  pop-
lation and,  consequently,  the  virus  required  more  time  to
pread.23
RVA  infections  were  predominant  in  children  aged  0--12
onths according  previous  reports,26 and  the  clinical  man-
festations varied  in  intensity  according  to  age  and  host
mmunity. The  classical  clinical  picture  of  RVA  infections  is
eported as  the  abrupt  onset  of  vomiting,  fever,  followed
y diarrhea,  and  leading  to  dehydration.25,27 It  is  worth  not-
ng that  seven  of  the  12  patients  affected  by  RVA  infection
ho required  hospitalization  were  admitted  to  the  ICU  with
evere dehydration,  did  not  have  underlying  diseases,  and
ere younger  than  six  months  old.
A  total  of  49.2%  of  the  hospitalized  children  was
ound to  have  moderate  or  severe  dehydration,  which
orroborates the  severity  of  this  infection.  However,  no  asso-
iation between  disease  severity  and  genotype  was  found,
emonstrating that  other  factors  (mainly  previous  clinical
onditions) may  be  associated  with  the  severity  and  intensity
f infections  caused  by  RVA.28
It  is  worth  mentioning  the  importance  of  RVA  associ-
ted to  hospital-acquired  infections  among  children.  Several
actors, such  as  age,  immune  status,  underlying  disease,
iagnostic and  therapeutic  interventions,  season  of  the  year,
nd duration  of  hospitalization  may  inﬂuence  the  acquisition
f these  infections.  In  addition  to  morbidity,  these  infections
ause a major  economic  impact  on  developed  and  devel-
ping countries.29 The  incidence  of  nosocomial  infections
n this  study  was  12.5%;  other  reports  found  rates  rang-
ng from  8%  to  33%.30 All  patients  had  serious  underlying
iseases and  this  infection  may  have  contributed  to  the
ncrease in  severity.  The  genotypes  found  in  these  patients
eﬂected the  same  genotype  circulating  in  the  community,
ighlighting the  importance  of  measures  for  hospital  infec-
ion control  to  prevent  the  spread  of  the  pathogen  in  this
nvironment.31
Epidemiological  studies  have  demonstrated  a  clear  cor-
elation between  RVA  circulation  period  and  increase  in
ediatric patient  admissions.  Although  no  speciﬁc  antiviral
herapy for  RVA  is  available,  the  identiﬁcation  of  infected
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284  
atients  is  important  to  prevent  nosocomial  transmission,  to
nderstand the  clinical  impact  of  these  infections,  to  guide
herapeutic measures  to  prevent  the  inappropriate  use  of
ntibiotics, and  to  indicate  the  need  for  speciﬁc  immuniza-
ion.
In conclusion,  this  study  has  demonstrated  the  genetic
ariability of  RVA  during  an  extensive  period  of  monitoring
nd the  severity  of  these  infections  in  pediatric  patients.  It
as also  emphasized  the  importance  of  ongoing  laboratory
urveillance to  detect  the  emergence  of  new  genotypes  and
o determine  whether  this  is  a  consequence  of  the  global
rogram of  immunization,  and  to  assess  its  impact  on  pedi-
tric health.
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